Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

ABSTRACT:

Background

CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients.

Methods

We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics.

Results

A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40);

SUBMITTER: Park JH 

PROVIDER: S-EPMC6637939 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature